Study #ALLIANCEA021501
ALLIANCE A021501- Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy For Borderline Resectable Adenocarcinoma Of The Head Of The Pancreas
MD Anderson Study Status
Not Accepting
Treatment Agent
mFOLFIRINOX, FOLFOX
Description
This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with or without hypofractionated radiation therapy before surgery works in patients with pancreatic cancer that can be removed by surgery. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if combination chemotherapy is more effective with or without hypofractionated radiation therapy before surgery in treating patients with pancreatic cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Study phase:
Phase II
Physician name:
Matthew Katz
Department:
Surgical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.